Patent awarded to neurohealth firm for non-invasive, frequency-based DBS device

A Houston-based neurohealth company has received a patent for its non-invasive, frequency-based deep brain stimulation device to address a range of psychiatric and neurologic conditions.

According to a release from Nexalin Technology Inc., the patent covers the core technology utilized in the company’s Gen-3 system, Transcranial Alternating Current Dynamic Frequency Stimulation, a proprietary and advanced waveform device that aims to treat patients in a painless and undetectable manner.

The Gen-3 system is applied through the placement of strategically positioned electrodes on the patient’s cranium, providing deep stimulation to regions of the brain associated with mental health, per the release.

“This patent marks what we believe is a major advancement for the drug-free treatment of mental health conditions,” Nexalin Technology CEO Mark White said in the release. “Recent published clinical evidence supports the clinical benefits of the Nexalin device for the treatment of a variety of neurological diseases associated with deep brain structures.”

White added that the company is planning on extending the reach of its novel device to address such conditions as addiction, substance use disorder, Alzheimer’s, traumatic brain injury and PTSD.